Is PT-141 (Bremelanotide) Legal in Alabama?
HealthRX.com
Vyleesi is the FDA-approved form of bremelanotide
See the public record for Bremelanotide
At a glance
- Federal status / FDA-approved as Vyleesi, NDA 210557, on June 21, 2019 [1][2]
- Approved use / Premenopausal women with acquired, generalized HSDD [1]
- Form and access / 1.75 mg subcutaneous autoinjector, prescription only [1]
- Boxed warning / None [1]
- Compounded or research PT-141 / Not Vyleesi; not an FDA-approved drug [3]
- FDA bulk-substance lists / Bremelanotide appears in no category [4][5][6]
- Anti-doping / Not named on WADA's 2026 Prohibited List [7]
What the FDA approved
Vyleesi (bremelanotide) was approved on June 21, 2019 under NDA 210557; the current holder is Cosette Pharmaceuticals [1][2]. It is a 1.75 mg subcutaneous injection in a prefilled autoinjector, prescription only [1]. The indication is narrow: acquired, generalized hypoactive sexual desire disorder in premenopausal women, meaning low sexual desire that causes marked distress or interpersonal difficulty and is not due to a medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label states it is not indicated for postmenopausal women or for men, and not to enhance sexual performance [1]. It carries no boxed warning and no risk evaluation and mitigation strategy [1][2].
The labeled dose is 1.75 mg into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. The label says not to give more than one dose in 24 hours and does not recommend more than 8 doses per month [1].
What 'PT-141' means when it is not Vyleesi
PT-141 is another name for bremelanotide. Peptides sold under that name as compounded products or as research-use vials are not Vyleesi and are not FDA-approved drugs, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before they are marketed [3][1].
Bremelanotide does not appear in any category on FDA's bulk-substance lists, including the list of bulk drug substances that may present significant safety risks [4][5]. It is also not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [6].
What the label says about cardiovascular risk and interactions
The label lists uncontrolled hypertension or known cardiovascular disease as contraindications and says Vyleesi is not recommended for people at high risk of cardiovascular disease. It says to consider cardiovascular risk and make sure blood pressure is well controlled before starting and periodically during treatment [1]. Each dose transiently raises blood pressure and lowers heart rate: in clinical studies, maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with a heart rate reduction of up to 5 beats per minute, usually back to baseline within 12 hours [1]. In a separate ambulatory study of 127 premenopausal women dosed once daily for 8 days, mean daytime blood pressure rose 1.9 mmHg systolic and 1.7 mmHg diastolic [1].
The label also says to avoid Vyleesi with oral naltrexone products intended to treat alcohol or opioid addiction; Vyleesi may significantly decrease naltrexone exposure [1].
Questions worth asking
Is bremelanotide restricted in sport?
Bremelanotide is not named on WADA's 2026 Prohibited List [7]. WADA's S0 class covers substances with no approval from any governmental health authority, which does not describe a drug FDA approved in 2019 [7][1].
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Frequently asked questions
Is PT-141 legal in Alabama?
Do I need a prescription for bremelanotide in Alabama?
Is compounded PT-141 legal?
Is bremelanotide approved for men or for postmenopausal women?
What is the approved dose and schedule?
Is bremelanotide on the WADA prohibited list?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Are non-FDA approved peptides legal?
The FDA material here does not settle that for peptides in general. It covers PT-141 (bremelanotide) only: compounded or research-use versions are not Vyleesi and are not FDA-approved, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before they are marketed. Bremelanotide appears in no category on FDA's bulk-substance lists.
What are the controlled substance prescription laws in Alabama?
The FDA records cited here are federal and do not describe any additional Alabama rules on prescribing or dispensing, so Alabama's controlled substance prescription laws are not established by this material. What is stated is that Vyleesi is labeled by FDA as a prescription-only product.
References
Show all 7 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration. Approval letter, NDA 210557, 2019. FDA approval letter for Vyleesi, NDA 210557
- Federal Register public inspection document 2026-22192.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration. Bulk drug substances list. FDA bulk drug substances document
- U.S. Department of Health and Human Services. 503A peptide enforcement discretion policy, Appendix B. HHS peptide enforcement discretion policy, Appendix B
- World Anti-Doping Agency. 2026 Prohibited List. WADA 2026 Prohibited List